Agios Pharmaceuticals (AGIO): $0.32 million was the positive money flow into the stock on Wednesday and the up/down ratio of ticks was also in favor of the bulls at 9.54. The value of trades done on upticks was $0.36 million, whereas, trades done on downticks were valued at $0.04 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0 million. Agios Pharmaceuticals (AGIO) fell $0.51 traded at $54.05, a change of -0.93% over the previous day. The stock is 1.91% for the week.
Shares of Agios Pharmaceuticals, Inc. rose by 3.67% in the last five trading days and 43.56% for the last 4 weeks. Agios Pharmaceuticals, Inc. is up 21.55% in the last 3-month period. Year-to-Date the stock performance stands at -16.5%.
Agios Pharmaceuticals (AGIO) : 3 brokerage houses believe that Agios Pharmaceuticals (AGIO) is a Strong Buy at current levels. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Agios Pharmaceuticals (AGIO). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 5 Wall Street Analysts endorse the stock as a Buy with a rating of 1.8.
Agios Pharmaceuticals (NASDAQ:AGIO): stock was range-bound between the intraday low of $52.38 and the intraday high of $54.99 after having opened at $54.65 on Wednesdays session. The stock finally closed in the red at $54.65, a loss of -0.62%. The stock remained in the red for the whole trading day. The total traded volume was 546,832 shares. The stock failed to cross $54.99 in Wednesdays trading. The stocks closing price on Thursday was $54.55.
Agios Pharmaceuticals, Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221, AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.